The executive responsible for Purdue Pharma Canada’s sales and marketing operation will be taking over the reins of the company.
David A. Pidduck was appointed the president and chief executive officer of the Pickering, Ont.-based pharmaceutical and healthcare firm earlier this week. He is replacing former president and CEO Dr. Craig Landau who was tasked to lead Purdue’s United States operations back in June this year.
Until this Monday’s announcement, Landau had retained his responsibility for Purdue Pharma Canada while also acting as president and CEO of the Purdue Pharma L.P., headquartered in Stamford, Conn.
Since joining Purdue Pharma Canada in 2014, Pidduck had been instrumental in diversifying the company’s product portfolio through alliances, partnerships and licensing agreements. He also leads the company’s commercial strategies across many therapeutic areas including pain, CNS, ophthalmology, and a growing over-the-counter portfolio.
“I have every confidence that David’s energy, commitment, skills, and experience will enable the team at Purdue Pharma Canada to continue to do the right things for the patients we serve and further grow a sustainable, integrated business here in Canada,” said Landau.
Before coming to Purdue, Pidduck held a series of directorial and executive positions at Baxter Corp. Canada where he worked from 1994 to 2013.
His international experience spans a wide array of disciplines, including sales, marketing, finance, business development and corporate strategy with more than 25 years of leadership experience in the life sciences industry.
“I’m honoured to have been chosen to lead the passionate and committed team of professionals and scientists that make Purdue Pharma Canada a great place to work,” said Pidduck. “I look forward to working with the team as we continue our efforts to develop, produce and bring to market innovative medicines and evidence-based information to support healthcare professionals and help patients and their families.”